Nasdaq
$7.00▼ 0.28%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $461.0MShares out 65.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 9.4After-hours26.09.05 08:044Ownership#●●●
Evolus, Inc.
Insider David Moatazedi of Evolus, Inc. filed a Form 4 on September 4, 2026, regarding a change in beneficial ownership of securities as of September 2, 2026. This filing serves as a standard disclosure of executive stock holdings and does not involve new share issuance or capital structure changes.…more
$7.00-0.28%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.2After-hours26.09.03 05:55144Ownership
Evolus, Inc.
Evolus, Inc. insider David Moatazedi has filed a Form 144 to report a proposed sale of company shares. This is a standard filing disclosing an insider's plan to dispose of their holdings.…more
$7.00-0.28%vs prev closeView filingShare - 8.31After-hours26.09.01 05:31SCHEDULE 13GOwnership
Evolus, Inc.
Six entities, including Soleus Capital Master Fund, L.P., entered into a Joint Filing Agreement on August 31, 2026, to collectively report their shareholdings in Evolus, Inc. Through this agreement, the parties have committed to jointly filing the Schedule 13G statement and any subsequent amendments.…more
$7.00-0.28%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.2Regular26.10.03 02:47Bullish#●●●
Evolus Receives FDA Warning Letter Over Misleading Jeuveau Social Media Ads…more
Evolus has been issued an FDA warning letter for exaggerating the efficacy and downplaying the risks of its frown line treatment, Jeuveau, in social media promotions. The company must submit a corrective plan within 15 days, and the regulatory action has negatively impacted its stock price.…more
$7.00-0.28%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.2Regular26.10.02 23:38
●●●●●●●● ●●●●● ●●●●●●
The FDA has sent a warning letter to Evolus, stating that promotional materials for its product JEUVEAU are misleading. This regulatory scrutiny may force the company to revise its marketing strategies and could impact future operational costs.…more
$7.00-0.28%vs prev closeShareBenzinga - 9.1Overnight26.09.01 16:59
●●●●●●●● ●●●●● ●●●●●●
Telix Pharmaceuticals has appointed David Gill as its new Board Chair, effective immediately. Former interim Chair Mark Nelson will continue to serve on the board as a non-executive director.…more
$7.00-0.28%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report